tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jul 6;10(7):1083.
doi: 10.3390/vaccines10071083.
Transplacental Transfer of Maternal Antibody against SARS-CoV-2 and Its Influencing Factors: A Review
Shuang Liu[SUP] 1 [/SUP], Jiayi Zhong[SUP] 1 [/SUP], Dingmei Zhang[SUP] 1 [/SUP]
Affiliations
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak, the disease has rapidly become a global threat. The constant emergence of new variants has increased the difficulty of controlling this disease. Vaccination is still considered the most effective method to prevent COVID-19. Vaccination has expanded to include children aged 3-17 years old, and some countries have lowered the age of vaccination to 6 months (for example, the United States). However, children under 3 years old are still not able to be vaccinated in most countries. In this study, we summarize the COVID-19 vaccination status in pregnant women, comprehensively elaborate on the status of maternal immune response and maternal antibody transfer after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, and further analyze the possible influencing factors of maternal antibody transfer according to the currently available evidence on the topic. It was concluded that pregnant women develop an immune response and produce antibodies that can be transmitted through the placenta after vaccination, but more data are needed to determine the transfer rate and duration of these maternal antibodies and potential factors. The results provide a scientific basis for studying the protective effect of maternal antibodies on infants, formulating a vaccination strategy for pregnant women, and preventing SARS-CoV-2 infection in infants.
Keywords: COVID-19 vaccine; antibodies transfer; maternal antibody; pregnancy.
. 2022 Jul 6;10(7):1083.
doi: 10.3390/vaccines10071083.
Transplacental Transfer of Maternal Antibody against SARS-CoV-2 and Its Influencing Factors: A Review
Shuang Liu[SUP] 1 [/SUP], Jiayi Zhong[SUP] 1 [/SUP], Dingmei Zhang[SUP] 1 [/SUP]
Affiliations
- PMID: 35891247
- DOI: 10.3390/vaccines10071083
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak, the disease has rapidly become a global threat. The constant emergence of new variants has increased the difficulty of controlling this disease. Vaccination is still considered the most effective method to prevent COVID-19. Vaccination has expanded to include children aged 3-17 years old, and some countries have lowered the age of vaccination to 6 months (for example, the United States). However, children under 3 years old are still not able to be vaccinated in most countries. In this study, we summarize the COVID-19 vaccination status in pregnant women, comprehensively elaborate on the status of maternal immune response and maternal antibody transfer after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, and further analyze the possible influencing factors of maternal antibody transfer according to the currently available evidence on the topic. It was concluded that pregnant women develop an immune response and produce antibodies that can be transmitted through the placenta after vaccination, but more data are needed to determine the transfer rate and duration of these maternal antibodies and potential factors. The results provide a scientific basis for studying the protective effect of maternal antibodies on infants, formulating a vaccination strategy for pregnant women, and preventing SARS-CoV-2 infection in infants.
Keywords: COVID-19 vaccine; antibodies transfer; maternal antibody; pregnancy.